Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.47 |
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6489104 | 0.91 | SIGMAR1 (0.46) | SIGMAR1FAAHPTGDR2TMEM97 | |
| SCHEMBL6496169 | 0.90 | TMEM97 (0.48) | SIGMAR1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL6487281 | 0.86 | TMEM97 (0.40) | SIGMAR1PTGDR2TMEM97 | |
| SCHEMBL6496625 | 0.85 | TMEM97 (0.45) | SIGMAR1MEN1KMT2ALMNAPTGDR2 | |
| SCHEMBL6495760 | 0.84 | TMEM97 (0.44) | SIGMAR1MEN1KMT2ATMEM97 | |
| SCHEMBL6487154 | 0.83 | TMEM97 (0.43) | SIGMAR1MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL6485731 | 0.82 | PTGDR2 (0.42) | SIGMAR1FAAHL3MBTL1MEN1KMT2A | |
| SCHEMBL6498455 | 0.82 | TMEM97 (0.37) | SIGMAR1MEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL6496283 | 0.82 | CHRM4 (0.45) | SIGMAR1ALDH1A1PTGDR2TMEM97 | |
| SCHEMBL6490718 | 0.82 | ALDH1A1 (0.39) | SIGMAR1MEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6869958-B2 | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-03-22 | — | — | US | disclosed |
| US-20040038960-A1 | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors | LI JIE JACK (US) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038960-A1 | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors | MMP9, MMP3, MMP13 | SIGMAR1 4243/4885FAAH 3450/4885L3MBTL1 3776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.